ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
PremiumPress ReleasesABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
3M ago
ABVC executes global licensing term sheet for oncology/hematology products
PremiumThe Fly
ABVC executes global licensing term sheet for oncology/hematology products
4M ago
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
PremiumPress Releases
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
4M ago
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
PremiumPress ReleasesABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
4M ago
ABVC BioPharma provides update on development of combination therapy
PremiumThe Fly
ABVC BioPharma provides update on development of combination therapy
5M ago
ABVC enters agreement to license certain healthcare-related expertise to SPI
PremiumThe Fly
ABVC enters agreement to license certain healthcare-related expertise to SPI
5M ago
ABVC BioPharma Conducts Private Equity and Warrants Sale
PremiumCompany AnnouncementsABVC BioPharma Conducts Private Equity and Warrants Sale
6M ago
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
PremiumPress Releases
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
6M ago
ABVC BioPharma acquires $2.96M worth of land in Asia
PremiumThe Fly
ABVC BioPharma acquires $2.96M worth of land in Asia
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100